Tissue Regenix Ltd - Completes £3m financing round and appoints Alan Miller as Non-Executive Director
30 Jan 2008
Tissue Regenix Limited (“Tissue Regenix” or “the Company”), the Leeds-based developer of revolutionary tissue products that regenerate inside the body, is delighted to announce that it has successfully completed a £3m financing round. Professor John Fisher, Chairman of Tissue Regenix, said: “I am delighted that Tissue Regenix has secured this investment which will enable the Company to accelerate our lead products into clinical trials.”
Tissue Regenix was founded in May 2006 by Professors Eileen Ingham and John Fisher as a spin-out from the University of Leeds to exploit innovative platform technologies in the field of tissue engineering and regenerative medicine. There is a well recognised clinical need for more donor tissue for many surgical procedures. Tissue Regenix is developing and commercialising the first truly regenerative tissue repair products to meet this need and, ultimately, benefit patients.
In addition, the Company is also pleased to announce that Alan Miller, the former Chief Investment Officer of New Star Asset Management, has joined the Board as a Non-Executive Director. Professor John Fisher said: “I am pleased to welcome Alan Miller to the Board. He brings a wealth of investment experience which will be invaluable to Tissue Regenix’s development.”
The Tissue Regenix technology addresses major clinical needs by allowing surgeons to use their products rather than wait for donor tissue or harvest it from the patient. Tissue Regenix products are not perceived as foreign bodies so they are gradually incorporated into the surrounding tissue by the body itself, repairing, replacing or providing strength and support to the repair site. For example, treated vascular tissue can replace a damaged blood vessel and treated ligament tissue would be used to repair ligament defects.
The Tissue Regenix biological scaffolds are unique because they behave and function just like the native tissue in almost every way - they are compatible with all blood and cell types, do not calcify and have similar biomechanical properties to the replaced tissue, allowing them to function as soon as they are implanted. Most importantly, the products then rapidly and successfully regenerate within the body.
For more information please contact:
Tissue Regenix 0870 803 2431
www.tissueregenix.com
Dr Simon Graindorge, Commercial Director 0113 384 5861
Notes for Editors
About Tissue Regenix Limited
Tissue Regenix Limited was formed in May 2006. The underpinning science was developed over the last decade by Professors John Fisher and Eileen Ingham as a result of their research and expertise in biocompatibility, immunocompatibility and functional tissue re-engineering.
Tissue Regenix products, which are produced from animal tissues, have an acellular architectural structure that is comparable to human tissue, and are therefore not perceived as foreign bodies by the host tissue. This lack of rejection allows the Tissue Regenix products to work by supporting fibroblast and smooth muscle cell infiltration, re-endothelialisation and revascularisation, so that it gradually becomes incorporated into the surrounding tissue, repairing, replacing or providing strength and support to the tissue defect.
Tissue Regenix Products are not allergenic or immunogenic. This is due in part to the fact that the collagen has an architectural structure very similar to human tissue. The Tissue Regenix tissue processing technology removes the cellular material whilst maintaining the essential extracellular matrix proteins, rendering it acellular and therefore non-allergenic or immunogenic.
The company is currently engaged in pre-clinical benchmarking and quality/regulatory work in support of preparation for clinical trials.
For more information, please visit our website at www.tissueregenix.com.
The University of Leeds
The University of Leeds has a long history of successful
entrepreneurial activity based on leading edge research, generating
more than seventy spinout companies to date. In the last 18 months
three companies have floated on AIM, raising some £10
million.
